10.73
Moonlake Immunotherapeutics stock is traded at $10.73, with a volume of 3.67M.
It is up +4.48% in the last 24 hours and down -79.63% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$10.26
Open:
$10.26
24h Volume:
3.67M
Relative Volume:
1.00
Market Cap:
$681.37M
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-4.6652
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
+23.79%
1M Performance:
-79.63%
6M Performance:
-69.28%
1Y Performance:
-78.10%
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MLTX
Moonlake Immunotherapeutics
|
10.73 | 651.52M | 0 | -145.21M | -140.12M | -2.30 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.56 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
469.33 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.46 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
800.99 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
330.86 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Sep-29-25 | Downgrade | Stifel | Buy → Hold |
Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
Nov-05-24 | Resumed | Wedbush | Outperform |
Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Jun-25-24 | Initiated | Oppenheimer | Outperform |
Apr-02-24 | Initiated | Goldman | Neutral |
Feb-15-24 | Initiated | Wolfe Research | Outperform |
Dec-08-23 | Initiated | Citigroup | Buy |
Nov-02-23 | Initiated | Stifel | Buy |
Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
Aug-31-23 | Initiated | Needham | Buy |
Jun-15-23 | Initiated | Barclays | Equal Weight |
May-01-23 | Initiated | Guggenheim | Buy |
Mar-22-23 | Initiated | Wedbush | Outperform |
Mar-09-23 | Initiated | BTIG Research | Buy |
Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
Feb-02-23 | Initiated | Bryan Garnier | Buy |
Nov-11-22 | Initiated | Jefferies | Buy |
Aug-25-22 | Initiated | SVB Leerink | Outperform |
Jul-21-22 | Initiated | H.C. Wainwright | Buy |
Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake ImmunotherapeuticsMLTX - PR Newswire
How to interpret RSI for MoonLake Immunotherapeutics stockMarket Weekly Review & Weekly Chart Analysis and Trade Guides - newser.com
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Chief Financial Officer of MoonLake Immunotherapeutics Matthias Bodenstedt Buys 1.8% More Shares - Yahoo Finance
MLTX SECURITIES NOTICE: MoonLake Immunotherapeutics - GlobeNewswire
Why Are MoonLake's (MLTX) Trial Setbacks Raising New Questions About Management Credibility and Regulatory Risks? - simplywall.st
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on - GuruFocus
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap UpShould You Buy? - MarketBeat
MLTX SECURITIES NOTICE: MoonLake Immunotherapeutics Securities Fraud Investigation is Pending – Contact BFA Law if You Lost Money - GlobeNewswire
CFO Makes Bold Move with Major Stock Purchase in MoonLake Immunotherapeutics - TipRanks
MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & - GlobeNewswire
Insider Stock Purchases: October 09, 2025 - Quiver Quantitative
MoonLake Immunotherapeutics Stock (MLTX) Opinions on Phase 3 Trial Setback - Quiver Quantitative
Bodenstedt, MoonLake CFO, buys $98k in MLTX stock By Investing.com - Investing.com Nigeria
Insider Buying: Matthias Bodenstedt Acquires Shares of MoonLake Immunotherapeutics - GuruFocus
Bodenstedt, MoonLake CFO, buys $98k in MLTX stock - Investing.com
BFA Law is Investigating MoonLake Immunotherapeutics (MLTX) for Securities Fraud and Urges Shareholders to Contact the Firm - Newsfile
Measuring MoonLake Immunotherapeutics’s beta against major indicesFed Meeting & Daily Growth Stock Tips - newser.com
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny - GlobeNewswire
MLTX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates - GlobeNewswire
MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with - GlobeNewswire
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Newsfile
Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors to Inquire About Securities Class Action InvestigationMLTX - Barchart.com
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
MLTX ALERT: Levi & Korsinsky Investigates MoonLake Immunotherapeutics on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Oppenheimer lowers Moonlake Immunotherapeutics stock price target after mixed trial results - Investing.com
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $25 - 富途牛牛
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics - GlobeNewswire
MoonLake Immunotherapeutics Investors Should Contact Block - GlobeNewswire
MLTX Investor News: If You Have Suffered Losses in MoonLake - GlobeNewswire
MLTX ACTIVE INVESTIGATION: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky Now - ACCESS Newswire
Levi & Korsinsky Investigates Possible Securities Fraud by MoonLake Immunotherapeutics (MLTX) - ACCESS Newswire
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm - The Malaysian Reserve
MoonLake Immunotherapeutics Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsMLTX - MarketScreener
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 9.9%Should You Buy? - MarketBeat
What is HC Wainwright’s Forecast for MLTX FY2025 Earnings? - Defense World
MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm’s Investigation - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MoonLake Immunotherapeutics (MLTX) And Encourages Investors to Reach Out - ACCESS Newswire
MoonLake Immunotherapeutics (MLTX): Valuation in Focus After VELA HS Trial Setback and Market Scrutiny - simplywall.st
Top 3 Health Care Stocks That Are Preparing To Pump In Q4 - Benzinga
Leading vs lagging indicators on MoonLake Immunotherapeutics performance2025 Fundamental Recap & Technical Buy Zone Confirmation - newser.com
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on - The National Law Review
Ongoing MoonLake Immunotherapeutics (MLTX) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Combining price and volume data for MoonLake ImmunotherapeuticsRisk Management & Daily Profit Focused Screening - newser.com
What earnings revisions data tells us about MoonLake ImmunotherapeuticsSwing Trade & AI Driven Stock Price Forecasts - newser.com
MoonLake Immunotherapeutics results for Phase 3 VELA-1, VELA-2 trials - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MoonLake Immunotherapeutics (MLTX) And Encourages Stockholders to Reach Out - ACCESS Newswire
ATTENTION MLTX Shareholders: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Did MoonLake Immunotherapeutics (MLTX) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
The week in pharma: action, reaction and insight – week to October 3 - The Pharma Letter
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Chen Bihua | Former 10% Owner |
Sep 29 '25 |
Sale |
7.21 |
6,494,151 |
46,827,628 |
2,000,000 |
Chen Bihua | Former 10% Owner |
Sep 30 '25 |
Sale |
6.96 |
5,827 |
40,556 |
1,994,173 |
Moukheibir Catherine | Director |
Jul 03 '25 |
Option Exercise |
0.00 |
23,500 |
0 |
23,500 |
Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):